Abstract
Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Current Pharmaceutical Design
Title: Lipid Management for the Prevention of Cardiovascular Disease
Volume: 17 Issue: 9
Author(s): Juergen R. Schaefer
Affiliation:
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Abstract: Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Export Options
About this article
Cite this article as:
R. Schaefer Juergen, Lipid Management for the Prevention of Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428849
DOI https://dx.doi.org/10.2174/138161211795428849 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Tuberculosis and Diabetes Mellitus in Northwest of Iran
Infectious Disorders - Drug Targets Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus
Current Neurovascular Research Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Protein Tyrosine Phosphatase 1B Inhibitors: A Novel Therapeutic Strategy for the Management of type 2 Diabetes Mellitus
Current Pharmaceutical Design Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Formulation and Pharmacodynamic Evaluation of Glibenclamide Incorporated Niosomal Gel
Current Drug Discovery Technologies Quantitative Gait Disturbances in Older Adults with Cognitive Impairments
Current Pharmaceutical Design Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature
Current Cardiology Reviews Risk Factors Associated with Resistance in CTX-M Producing E. coli Isolates
Current Drug Therapy The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Pharmacogenomics and Personalized Use of Drugs
Current Topics in Medicinal Chemistry Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry